Black Pearl Raises Bid to $5.05/Share for Selectis Health (GBCS)

The Offer

Black Pearl Equities, LLC has commenced a cash tender offer to acquire all outstanding shares of Selectis Health, Inc. (OTCQB: GBCS) at $5.05 per share. Selectis operates senior housing and skilled nursing facilities across the southeastern United States. The offer, filed via Schedule TO with the SEC, represents a roughly 45% premium to where GBCS was trading at the time of the announcement and a 32.9% spread to the current price of $3.80.

The offer expires at 5:00 p.m. Eastern on May 11, 2026, unless extended or terminated early. D.F. King & Co. is serving as information agent, and Equiniti Trust Company is the depositary. This is a third-party, unsolicited bid — Black Pearl does not have a definitive acquisition agreement with Selectis, and the board has not yet formally responded. According to the SC TO-T filing, Black Pearl approached the Selectis board in late October 2025 and followed up in January 2026. The parties signed an NDA in February, but Selectis never opened a data room — so Black Pearl went directly to shareholders.

Why This Is Interesting

The 32.9% gross spread is enormous by tender offer standards, and it tells you the market sees real risk here. For context, typical definitive cash deals trade at spreads of 1–5%. The discount reflects three things: this is unsolicited with no board recommendation, Black Pearl has a history of walking away from deals, and GBCS is a thinly-traded OTC stock where liquidity risk compounds everything else.

That said, the price bump from $4.00 to $5.05 between the preliminary communication and the formal filing is notable. It suggests Black Pearl is serious enough to raise its bid before the offer even launched — possibly to pre-empt board opposition or to attract enough tenders to meet the 51% minimum condition. If the board ultimately recommends the deal or stays neutral, and 51% of shares get tendered, the risk/reward calculus shifts significantly. At $3.80, you'd be looking at a $1.25/share gain over roughly two months if the deal closes.

Key Terms

• Offer price: $5.05 per share, net cash, no interest, subject to tax withholding
• Shares sought: All outstanding common shares (approximately 3.07 million shares, implying a total deal value of roughly $15.5 million)
• Minimum tender condition: At least 51% of outstanding shares must be validly tendered and not withdrawn — this is the critical hurdle
• Expiration: May 11, 2026, at 5:00 p.m. ET, subject to extension
• Board recommendation: Not yet issued. Selectis is required to file a Schedule 14D-9 within 10 business days of the offer's commencement
• Financing: Funded by Milrose Capital, LLC from cash on hand. No loan arrangements — this is a fully cash-funded deal with no financing contingency
• Regulatory approvals: The filing references required regulatory and governmental consents, consistent with healthcare sector acquisitions
• Material adverse change condition: Broad MAC clause — if Selectis enters into mergers, sells assets, takes on material liabilities, or makes payments outside the ordinary course (executive bonuses, dividends, equity acceleration), Black Pearl can reduce the offer price or terminate entirely
• Poison pill waiver required: Selectis must waive or terminate its Rights Agreement before Black Pearl is obligated to close
• 9.8% ownership cap waiver required: The company's charter limits any holder to 9.8% of shares (REIT provision) — this must be waived for the deal to work
• Due diligence condition: Selectis must provide reasonable access to customary due diligence materials — they haven't done so yet, making this a key condition to watch
• Withdrawal rights: Tendered shares may be withdrawn any time before expiration, and after May 9, 2026 (60 days from commencement) if shares haven't been accepted for payment
• Odd-lot provisions: None disclosed in the filing. No preferential treatment for small holders
• Oversubscription: Pro rata return of any oversubscribed shares

Timeline

Risks

• Board opposition is the biggest wildcard. The Selectis board has not responded to the offer, and the press release explicitly contemplates defensive measures or competing bids. If the board recommends against tendering, reaching the 51% minimum becomes much harder with a fragmented OTC shareholder base.
• Black Pearl walked away before. In July 2025, Black Pearl launched a $4.25/share bid for up to 49.9% of Regional Health Properties (RHEP) and terminated it in August 2025 without purchasing a single share. The firm cited corporate structure changes at RHEP as the trigger. The same playbook could repeat here.
• Due diligence standoff. The SC TO-T reveals that Selectis signed an NDA but never opened a data room. Black Pearl is required to receive due diligence access before it must close — if the board stonewalls, this becomes a convenient exit ramp for the offeror, similar to what happened with RHEP.
• 51% minimum tender condition on an OTC stock. Reaching 51% on a thinly-traded OTC name requires broad shareholder participation. If insiders or large holders decline to tender, the math gets tight quickly. There is no public disclosure yet on insider ownership levels or their intentions.
• OTC liquidity risk. GBCS trades on the OTCQB with limited volume. If the deal falls apart, exiting a position could be slow and costly. The bid-ask spread on OTC names can widen dramatically on bad news.
• Going concern history. Selectis has previously expressed substantial doubt about its ability to continue as a going concern. While this could make the $5.05 offer more attractive to shareholders eager for an exit, it also means the underlying business carries fundamental risk if the deal collapses.
• Poison pill and charter defenses. Selectis has a Rights Agreement and a 9.8% ownership cap in its charter. Both must be waived for the deal to close. If the board refuses to cooperate, these structural defenses could block the acquisition entirely.
• Price reduction clause. The SC TO-T gives Black Pearl the right to reduce the $5.05 price if Selectis takes certain actions — merging, selling assets, paying bonuses, or incurring new liabilities. This gives the board limited room to maneuver without potentially triggering a lower offer.
• Healthcare regulatory approvals. Senior housing and skilled nursing facility acquisitions may require state-level health department review, which can introduce delays.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.